Synergistic Anti‐Tumor Effect of Chidamide and Linperlisib on Natural Killer/T‐Cell Lymphoma by Inhibiting PI3K/AKT/mTOR Pathway
Natural killer/T‐cell lymphoma (NKTCL) is an aggressive lymphoma subtype with limited treatment options, especially for relapsed or refractory patients. Chidamide, a histone deacetylase inhibitor, and linperlisib, a phosphatidylinositol‐3‐kinase (PI3K) inhibitor, have shown promise in treating peripheral T‐cell lymphom...